Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
18 juin 2020 07h57 HE
|
Aptinyx Inc.
EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at Upcoming Virtual Investor Conferences
16 juin 2020 08h37 HE
|
Aptinyx Inc.
EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
14 mai 2020 16h03 HE
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
30 avr. 2020 08h47 HE
|
Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
30 mars 2020 16h01 HE
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
18 mars 2020 16h01 HE
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present at Upcoming Investor Conferences
19 févr. 2020 08h37 HE
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
30 janv. 2020 07h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
14 janv. 2020 16h01 HE
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Announces Pricing of Public Offering of Common Stock
10 janv. 2020 09h00 HE
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...